Sr.
No. |
Cytological
Diagnosis |
No.
of Cases |
Total
(%) |
|
Male
(%) |
Female
(%) |
|||
1. |
Tuberculous
Lymphadenitis |
61
(41.8) |
85
(58.2) |
146
(54.5) |
2. |
Reactive
Hyperplasia |
12
(57.1) |
09
(42.9) |
21
(7.8) |
3. |
Granulomatous
Lymphadenitis |
18
(40.0) |
27
(60.0) |
45
(16.8) |
4. |
Metastatic
Carcinoma |
17
(60.7) |
11
(39.3) |
28
(10.4) |
5. |
Hodgkin’s
Lymphoma |
02
(100.0) |
- |
02
(0.8) |
6. |
Non-Hodgkin’s
Lymphoma |
03
(75.0) |
01
(25.0) |
04
(1.5) |
7. |
Acute
Suppurative Lymphadenitis |
13
(61.9) |
08
(38.1) |
21
(7.8) |
8. |
Others (Fungal
Infection) |
- |
01
(100.0) |
01
(0.4) |
9. |
Total |
126
(47.0) |
142
(53.0) |
268
(100.0) |
Age
Group (in
Years) |
No.
of Males (%) |
No.
of Females (%) |
Total
(%) |
<
10 |
05
(1.9) |
04
(1.5) |
09
(3.4) |
11-20 |
17
(6.3) |
23
(8.6) |
40
(14.9) |
21-30 |
41
(15.3) |
50
(18.7) |
91
(34.0) |
31-40 |
30
(11.2) |
32
(11.9) |
62
(23.1) |
41-50 |
14
(5.2) |
13
(4.9) |
27
(10.1) |
51-60 |
09
(3.3) |
09
(3.3) |
18
(6.7) |
>60 |
10
(3.7) |
11
(4.1) |
21
(7.8) |
Total |
126
(47.0) |
142
(53.0) |
268
(100.0) |
Cytomorphological
Diagnosis |
Cervical |
Axillary |
Supra-clavicular |
Inguinal |
Generalised |
Total
(%) |
Tuberculous
Lymphadenitis |
119 |
05 |
12 |
02 |
08 |
146
(54.5) |
Reactive
Hyperplasia |
09 |
07 |
03 |
- |
02 |
21
(7.8) |
Granulomatous
Lymphadenitis |
14 |
18 |
12 |
01 |
- |
45
(16.8) |
Metastatic
Carcinoma |
12 |
09 |
05 |
02 |
- |
28
(10.4) |
Hodgkin’s
Lymphoma |
01 |
- |
01 |
- |
- |
02
(0.8) |
Non-Hodgkin’s
Lymphoma |
02 |
- |
- |
01 |
01 |
04
(1.5) |
Acute
Suppurative Lymphadenitis |
11 |
06 |
03 |
01 |
- |
21
(7.8) |
Others |
- |
01 |
- |
- |
- |
01
(0.4) |
Total |
168
(62.7) |
46
(17.2) |
36
(13.4) |
07
(2.6) |
11
(4.1) |
268
(100.0) |
Age
Group |
Sex |
Cervical |
Axillary |
Supra-clavicular |
Inguinal |
General |
Total |
Total (M+F) |
<
10 |
Male |
03 |
01 |
- |
01 |
- |
05 |
09 (3.4%) |
Female |
02 |
01 |
01 |
- |
- |
04 |
||
11-20 |
Male |
08 |
03 |
05 |
- |
01 |
17 |
40 (14.9%) |
Female |
12 |
05 |
03 |
01 |
02 |
23 |
||
21-30 |
Male |
30 |
08 |
02 |
- |
01 |
41 |
91 (34.0%) |
Female |
36 |
07 |
05 |
01 |
01 |
50 |
||
31-40 |
Male |
16 |
06 |
05 |
01 |
02 |
30 |
62 (23.1%) |
Female |
22 |
04 |
04 |
01 |
01 |
32 |
||
41-50 |
Male |
09 |
02 |
02 |
01 |
- |
14 |
27 (10.1%) |
Female |
09 |
02 |
01 |
- |
01 |
13 |
||
51-60 |
Male |
04 |
02 |
03 |
- |
- |
09 |
18 (6.7%) |
Female |
05 |
01 |
02 |
- |
01 |
09 |
||
>60 |
Male |
06 |
02 |
01 |
- |
01 |
10 |
21 (7.8%) |
Female |
06 |
02 |
02 |
01 |
- |
11 |
||
Total |
168
(62.7%) |
46 (17.2%) |
36 (13.4%) |
07 (2.6%) |
11 (4.1%) |
268 (100.0%) |
268 (100.0%) |
Age
Group |
Sex |
Tuber-culous |
Reactive |
Granulo-matous |
Metastatic |
Hodgkin’s |
Non-Hodgkin’s |
Acute
Suppurative |
Others |
Total |
<
10 |
Male |
02 |
01 |
01 |
- |
- |
- |
01 |
- |
05 |
Female |
03 |
- |
01 |
- |
- |
- |
- |
- |
04 |
|
11-20 |
Male |
09 |
01 |
02 |
- |
01 |
- |
04 |
- |
17 |
Female |
13 |
02 |
05 |
- |
- |
- |
03 |
- |
23 |
|
21-30 |
Male |
25 |
02 |
05 |
02 |
01 |
- |
06 |
- |
41 |
Female |
37 |
02 |
07 |
- |
- |
- |
03 |
01 |
50 |
|
31-40 |
Male |
17 |
04 |
06 |
01 |
- |
- |
02 |
- |
30 |
Female |
21 |
02 |
09 |
- |
- |
- |
- |
- |
32 |
|
41-50 |
Male |
05 |
02 |
02 |
04 |
- |
01 |
- |
- |
14 |
Female |
07 |
01 |
02 |
02 |
- |
- |
01 |
- |
13 |
|
51-60 |
Male |
02 |
- |
01 |
05 |
- |
01 |
- |
- |
09 |
Female |
02 |
02 |
02 |
03 |
- |
- |
- |
- |
09 |
|
>60 |
Male |
01 |
02 |
01 |
05 |
- |
01 |
- |
|
10 |
Female |
02 |
- |
01 |
06 |
- |
01 |
01 |
- |
11 |
|
Total
Male |
61 |
12 |
18 |
17 |
02 |
03 |
13 |
00 |
126 |
|
Total
Female |
85 |
09 |
27 |
11 |
00 |
01 |
08 |
01 |
142 |
|
Total
(M+F) |
146 (54.5%) |
21 (7.8%) |
45 (16.8%) |
28 (10.4%) |
02 (0.8%) |
04 (1.5%) |
21 (7.8%) |
01 (0.4%) |
268 (100.0%) |